Sedatives/ Hypnotics denials: 33.8% overturned by independent reviewers
In 77 California IMR decisions from 2004 to 2026, reviewers overturned the plan 26 times (33.8%). In the last five years: 40.0% of 35. Denials reach IMR only when a member appeals all the way; read the caveats below before generalising.
By diagnosis
| Diagnosis category | Decisions | Overturned | Last 5 years |
|---|---|---|---|
| CNS/ Neuromusc Dis | 42 | 42.9% | 47.6% of 21 |
| Mental Disorder | 25 | 28.0% | 27.3% of 11 |
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 9 | 44.4% |
| 2022 | 6 | 0.0% |
| 2023 | 9 | 22.2% |
| 2024 | 5 | 60.0% |
| 2025 | 5 | 80.0% |
| 2026 | 1 | 100.0% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Records did not supportThe findings say the documentation did not show what was needed (usually an upheld denial). | 24 | 0.0% | 33.8% |
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 22 | 31.8% | 33.8% |
| Prior therapies failedThe findings mention treatments that were tried without adequate response. | 16 | 43.8% | 33.8% |
| Step therapy or fail-firstThe findings mention a fail-first requirement. | 8 | 25.0% | 33.8% |
| FDA approval or off-label use discussedThe findings discuss the FDA label status of the treatment. | 7 | 42.9% | 33.8% |
| Guidelines or criteria citedThe findings cite guidelines, criteria or a standard of care. | 7 | 28.6% | 33.8% |
| Alternatives contraindicatedThe findings mention a contraindication to the plan's preferred option. | 6 | 16.7% | 33.8% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“The physician reviewer found that a patient has requested authorization and coverage for Lumryz. Expert guidelines for central disorders of hypersomnolence recommend sodium oxybate as an evidence‑based therapy for narcolepsy due to its demonstrated efficacy in improving excessive daytime sleepiness and cataplexy. Lumryz is a U.S. Food and Drug Administration (FDA)‑approved once‑nightly sodium oxybate formulation that may improve adherence and …”
“The physician reviewer found that a patient’s parent has requested authorization and coverage for Xywav. Per the medical records, given that the use of Xywav is consistent with evidence-based guidelines for the patient's condition, and as the records indicate that the patient meets the clinical criteria for use of Xywav, including age indication, documented diagnosis, failure of first-line therapy, and …”
“Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Xywav 0.5 g/mL solution.The U.S. Food and Drug Administration (FDA) approved Xywav 0.5 g/mL oral solution for the treatment of narcolepsy with cataplexy or excessive daytime sleepiness in patients seven years of age and older. The FDA noted that Xywav is clinically superior to Xyrem because Xywav …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Sedatives/ Hypnotics denials overturned?
In 77 California IMR decisions from 2004 to 2026, reviewers overturned the plan 26 times (33.8%). In the last five years: 40.0% of 35.
What did the reviewers' findings mention in overturned cases?
The table on this page counts keyword matches in the findings: prior therapies tried, contraindications, guidelines cited, published evidence, whether the records supported the request. They describe what the findings say, not why the case was decided.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but the reasoning is the same kind: criteria, documentation and alternatives. Use the findings as a guide to what to document.
Related: California appeal rights · California external-review reversal rate · The levers library · CSV
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.